Malnutrition and wasting in renal disease

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 12, Issue 4, 2009, Pages 378-383

  Muscaritoli, Maurizio ^a   Molfino, Alessio ^a,b   Bollea, Maria Rosa ^b   Fanelli, Filippo Rossi ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Acidosis; End stage renal disease; Inflammation; Malnutrition; Muscle wasting

Indexed keywords

ACETYLCYSTEINE; ADENOSINE TRIPHOSPHATE; ALBUMIN; ALPHA TOCOPHEROL; AMINO ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BICARBONATE; CALPAIN; CARNITINE; CASPASE 3; CATHEPSIN B; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; LIVER PROTEIN; MESSENGER RNA; MUSCLE PROTEIN; MYOSTATIN; PROTEASOME; RECOMBINANT INTERLEUKIN 6; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UNINDEXED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALBUMIN BLOOD LEVEL; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ARTIFICIAL FEEDING; CACHEXIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG BLOOD LEVEL; ENTERIC FEEDING; FIBRINOGEN BLOOD LEVEL; HEART FAILURE; HEMODIALYSIS; HUMAN; HYPOBICARBONATEMIA; HYPOCAPNIA; INFLAMMATION; INSULIN RESISTANCE; KIDNEY FAILURE; MALNUTRITION; METABOLIC ACIDOSIS; MUSCLE ATROPHY; MUSCLE METABOLISM; NONHUMAN; NUTRITIONAL SUPPORT; OXIDATIVE STRESS; PARENTERAL NUTRITION; PATHOGENESIS; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CALORIE MALNUTRITION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN RESTRICTION; PROTEIN SYNTHESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIGNAL TRANSDUCTION; VITAMIN SUPPLEMENTATION; VOMITING; WASTING SYNDROME; WEIGHT REDUCTION;

ANTIOXIDANTS; CYTOKINES; ENERGY METABOLISM; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; LIVER; OXIDATIVE STRESS; PARENTERAL NUTRITION; PROTEIN-ENERGY MALNUTRITION; PROTEINS; RENAL DIALYSIS; WASTING SYNDROME;

EID: 68049102220     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0b013e32832c7ae1     Document Type: Review

References (77)

1. Locatelli F, Fouque D, Heimburger O, et al. Nutritional status in dialysis patients: a European consensus. Nephrol Dial Transplant 2002; 17:563-572.
2. KDOQI, National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47 (5 Suppl 3):S11-S145.
3. Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int 2008; 73:391-398. An excellent state-of-the-art document on the definition and assessment of malnutrition in renal disease.
4. Kalantar-Zadeh K. Recent advances in understanding the malnutrition-inflammation-cachexia syndrome in chronic kidney disease patients: what is next? Semin Dial 2005; 18:365-369.
5. Evans WJ, Morley JE, Argilés J, et al. Cachexia: a new definition. Clin Nutr 2008; 27:793-799.
6. Bergstrom J, Lindholm B. Nutrition and adequacy of dialysis. How do hemodialysis and CAPD compare? Kidney Int Suppl 1993; 43:S39-S50.
7. Aparicio M, Cano N, Chauveau P, et al. Nutritional status of hemodialysis patients: a French National Cooperative Study. Nephrol Dial Transplant 1999; 14:1679-1686.
8. Stenvinkel P, Heimburger O, Lindholm B. Wasting, but not malnutrition, predicts cardiovascular mortality in end-stage renal disease. Nephrol Dial Transplant 2004; 19:2181-2183.
9. Kalantar-Zadeh K, Block G, McAllister CJ, et al. Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr 2004; 80:299-307.
10. Bossola M, Muscaritoli M, Valenza V, et al. Anorexia and serum leptin levels in hemodialysis patients. Nephron Clin Pract 2004; 97:c76-c82.
11. Muscaritoli M, Molfino A, Chiappini MG, et al. Anorexia in hemodialysis patients: the possibile role of des-acyl ghrelin. Am J Nephrol 2007; 27: 360-365.
12. Raff AC, Lieu S, MelamedML, et al. Relationship of impaired olfactory function in end-stage renal disease to malnutrition and retained uremic molecules. Am J Kidney Dis 2008; 52:102-110. An interesting study providing new insights into the pathogenic mechanisms of uremic anorexia.
13. Stenvinkel P, Lindholm B, Lonnqvist F, et al. Increases in serum leptin levels during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. J Am Soc Nephrol 2000; 11:1303-1309.
14. Pecoits-Filho R, Nordfors L, Heimburger O, et al. Soluble leptin receptors and serum leptin in end-stage renal disease: relationship with inflammation and body composition. Eur J Clin Invest 2002; 32:811-817.
15. Kopple JD. National Kidney Foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 2001; 37:S66-S70.
16. Du J, Zhaoyong H, Mitch WE. Cellular signal activating muscle proteolysis in chronic kidney disease: a two-stage process. Int J Biochem Cell Biol 2005; 37:2147-2155.
17. Costelli P, Reffo P, Penna F, et al. Ca-dependent proteolysis in muscle wasting. Int J Biochem Cell Biol 2005; 37:2134-2146.
18. Mitch WE, Goldberg AL. Mechanisms of muscle wasting: the role of the ubiquitin-proteasome system. N Engl J Med 1996; 335:1897.
19. Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitinproteasome pathway in normal and disease states. J Am Soc Nephrol 2006; 17:1807.
20. Lecker SH, Jagoe RT, Gomes M, et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 2004; 18:39-51.
21. Lee S, Dai G, Hu Z, et al. Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol 2004; 15:1537-1545.
22. Pickering WP, Price SR, Bircher G, et al. Nutrition in CAPD: serum bicarbonate and the ubiquitin-proteasome system in muscle. Kidney Int 2002; 61:1286-1292.
23. Bossola M, Muscaritoli M, Costelli P, et al. Muscle ubiquitin m-RNA levels in patients with end-stage renal disease on maintenance hemodialysis. J Nephrol 2002; 15:552-557.
24. Du J, Wang X, Meireles C, et al. Activation of caspase 3 is an initial step triggering muscle proteolysis in catabolic conditions. J Clin Invest 2004; 113:115-123.
25. Workeneh B, Rondon-Berrios H, Zhang L, et al. Development of a diagnostic method for detecting increased muscle protein degradation in patients with catabolic conditions. J Am Soc Nephrol 2006; 17:3233.
26. Raj DSC, Shah H, Shah VO, et al. Markers of inflammation, proteolysis, and apoptosis in end-stage renal disease. Am J Kidney Dis 2003; 6:1212-1220.
27. Kadowaki M, Kanazawa T. Amino acids as regulators of proteolysis. J Nutr 2003; 133:2052S-2056S.
28. Bosutti A, Toigo G, Ciocchi B, et al. Regulation of muscle cathepsin B proteolytic activity in protein-depleted patients with chronic diseases. Clin Nutr 2002; 21:373-378.
29. HeszeleMFC, Price SR. Insulin-like growth factor I: the yin and yang of muscle atrophy. Endocrinology 2004; 145:4803-4805.
30. Tönshoff B, Kiepe D, Ciarmatori S. Growth hormone/insulin-like growth factor system in children with chronic renal failure. Pediatr Nephrol 2005; 20:279-289.
31. Joulia-Ekaza D, Cabello G. The myostatin gene: physiology and pharmacological relevance. Curr Opin Pharmacol 2007; 7:310-315.
32. Sun DF, Chen Y, Rabkin R. Work-induced changes in skeletal muscle IGF-1 and myostatin gene expression in uremia. Kidney Int 2006; 70:453-459.
33. Cheung WW, Rosengren S, Boyle DL, Mak RH. Modulation of melanocortin signalling ameliorates uremic cachexia. Kidney Int 2008; 74:180-186.
34. Kaysen GA, Schoenfeld PY. Albumin homeostasis in patients undergoing continuous ambulatory peritoneal dialysis. Kidney Int 1984; 25:107-114.
35. Raj DSC, Moseley P, Dominic EA, et al. Interleukin-6 modulates hepatic and muscle protein synthesis during haemodialysis. Kidney Int 2008; 73:1054-1061. An outstanding clinical study showing the relationships between IL-6 and muscle catabolism in hemodialysis patients.
36. Ballmer PE, McNurlan MA, Hulter HM, et al. Chronic metabolic acidosis decreases albumin synthesis and induces negative nitrogen balance in humans. J Clin Invest 1995; 95:39-45.
37. May RC, Kelly RA, Mitch WE. Mechanisms for defects in muscle protein metabolism in rats with chronic uremia: the influence of metabolic acidosis. J Clin Invest 1987; 79:1099-1103.
38. Eustace JA, Astor B, Muntner PM, et al. Prevalence of acidosis and inflammation and their association with low serum albumin in chronic kidney disease. Kidney Int 2004; 65:1031-1040.
39. Movilli E, Zani R, Carli O, et al. Correction of metabolic acidosis increases serum albumin concentrations and decreases kinetically evaluated protein intake in haemodialysis patients: a prospective study. Nephrol Dial Transplant 1998; 13:1719-1722.
40. Brady JP, Hasbargen JA. Correction of metabolic acidosis and its effect on albumin in chronic hemodialysis patients. Am J Kidney Dis 1998; 31:35-40.
41. Pecoits-Filoh R, Sylvestre LC, Stenvinkel P. Chronic kidney disease and inflammation in pediatric patients: from bench to playground. Pediatr Nephrol 2005; 20:714-720.
42. Kaizu Y, Ohkawa S, Odamaki M, et al. Association between inflammatory mediators and muscle mass in long-term hemodialysis patients. Am J Kidney Dis 2003; 42:295-302.
43. Halaas J, Gajiwala KS, Maffei M, et al. Weight-reducing effects of plasma protein encoded by the obese gene. Science 1995; 269:543-549.
44. Sharma K, Considine RW, Michael B, et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int 1997; 51:1980-1985.
45. Goodman MN. Interleukin-6 induces skeletal muscle protein breakdown in rats. Proc Soc Exp Biol Med 1994; 205:182-185.
46. Raj DS, Adeniyi O, Dominic EA, et al. Amino acid repletion does not decrease muscle protein catabolism during hemodialysis. Am J Physiol 2007; 292:E1534-E1542.
47. Guttridge DC, Maio MW, Madrid LV, et al. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000; 289:2363-2366.
48. Aguilera A, Codeco R, Selgas R, et al. Anorexigen (TNF alpha, cholecystochinin) and orexigen (neuropeptide Y) in peritoneal dialysis patients. Their relationship with nutritional parameters. Nephrol Dial Transplant 1998; 13: 1476-1483.
49. Elkington JR. Hydrogen ion turnover in renal health and disease. Ann Intern Med 1962; 57:660-684.
50. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decrease kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41:1-12.
51. Williams AJ, Dittmer ID, McArley A, Clarke J. High bicarbonate dialysate in haemodialysis patients: effects on acidosis and nutritional status. Nephrol Dial Transplant 1997; 12:2633-2637.
52. Bossola M, Giungi S, Tazza L, Luciani G. Long-term oral sodium bicarbonate supplementation does not improve serum albumin levels in hemodialysis patients. Nephron Clin Pract 2007; 106:c51-c56.
53. Handelman GJ. Current studies on oxidant stress in dialysis. Blood Purif 2003; 21:46-50.
54. Locatelli F, Canaud B, Eckardt KU, et al. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18:1272-1280.
55. Nguyen-Khoa T, Massy ZA, De Bandt JP, et al. Oxidative stress and haemodialysis: role of inflammation and duration of dialysis treatment. Nephrol Dial Transplant 2001; 16:335-340.
56. Mezzano D, Pais EO, Aranda E, et al. Inflammation, not homocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia. Kidney Int 2001; 60:1844-1850.
57. Powers SK, Kavazis AN, De Ruisseau KC. Mechanism of disuse muscle atrophy: role of oxidative stress. Am J Physiol Regul Integr Comp Physiol 2005; 288:R337-R344.
58. Clermont G, Lecour S, Cabanne JF, et al. Vitamin E-coated dialyzer reduces oxidative stress in hemodialysis patients. Free Radic Biol Med 2001; 31:233-241.
59. Lonn E, Yusuf S, Hoogwerf B, et al. Effects of vitamin E on cardiovascular and microvascular outcomes in high risk patients with diabetes: result from the HOPE study and MICRO-HOPE substudy. Diabetes Care 2002; 25:1919-1927.
60. Price SR, Bailey JL, Wang X, et al. Muscle wasting in insulinopenic rats result from activation of the ATP dependent ubiquitin-proteasome proteolytic pathway by mechanism including gene expression. J Clin Invest 1996; 98:1703-1708.
61. Siew ED, Pupim LB, Majchrzak KM, et al. Insulin resistance is associated with skeletal muscle protein breakdown in nondiabetic chronic hemodialysis patients. Kidney Int 2007; 71:146-152.
62. Tom K, Young VR, Chapman T, et al. Long-term adaptive responses to dietary protein restriction in chronic renal failure. Am J Physiol 1995; 268:E668-E677.
63. Ruilope LM. Angiotensin receptor blocker: RAAS blockade and renoprotection. Curr Med Res Opin 2008; 24:1285-1293. An exhaustive review of the effects of RAAS-blocking agents on the progression of chronic kidney disease.
64. Mitch WE. Requirements for protein, calories and fat in predialysis patients. In: Mitch WE, Klahr S, editors. Handbook of nutrition and the kidney. Philadelphia: Lippincott, Williams and Wilkins; 2002. pp. 144-165.
65. Veenam JM, Kingma HA, Boer ST, et al. Protein intake during hemodialysis maintains a positive whole body protein balance in chronic hemodialysis patients. Am J Physiol Endocrinol Metab 2003; 284:E954-E965.
66. Tepel M, van der Giet M, StatsM, et al. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003; 107:992-995.
67. Szeto CC, Wong TY, Chow KM, et al. Oral sodium bicarbonate for the treatment of metabolic acidosis in peritoneal dialysis patients: a randomized placebo-control trial. J Am Soc Nephrol 2003; 14:2119-2126.
68. Kraut JA, Kurtz I. Metabolic acidosis of chronic kidney disease: diagnosis, clinical characteristics and treatment. Am J Kidney Dis 2005; 45:978-993.
69. Muscaritoli M, Bossola M, Bellantone R, Rossi Fanelli F. Therapy of muscle wasting in cancer: what is the future? Curr Opin Clin Nutr Metab Care 2004; 7:459-466.
70. Stenvinkel P, Andersson P, Wang T. Do ACE-inhibitors suppress tumor necrosis factor-alpha production in advanced chronic renal failure? J Intern Med 1999; 246:503-507.
71. Savica V, Santoro D, Mazzaglia G, et al. L-carnitine infusions may suppress serum C-reactive protein and improve nutritional status in maintenance hemodialysis patients. J Ren Nutr 2005; 15:225-230.
72. Pupim L, Flakoll PJ, Broillette JR, et al. Intradialytic parenteral nutrition improves protein and energy homeostasis in chronic hemodialysis patients. J Clin Invest 2002; 110:483-492.
73. Pupim L, Flakoll PJ, Ikizler TA. Nutritional supplementation acutely increases albumin fractional synthetic rate in chronic hemodialysis patients. J Am Soc Nephrol 2004; 15:1920-1926.
74. Bossola M, Muscaritoli M, Tazza L, et al. Malnutrition in hemodialysis patients: what therapy? Am J Kidney Dis 2005; 46:371-386.
75. Fiaccadori E, Maggiore U, Giacosa L, et al. Enteral nutrition in patients with acute renal failure. Kidney Int 2004; 65:999-1008.
76. Coleman JE, Watson AR, Rance CH, Moore E. Gastrostomy buttons for nutritional support on chronic dialysis. Nephrol Dial Transplant 1998; 13:2041-2046.
77. ESPEN. European Society for Enteral and Parenteral Nutrition guidelines on nutrition support in renal failure. Clin Nutr 2006; 25:195-310.